Creo Medical Group Plc · LSE:CREO
Creo Medical — Investor Presentation (March 2023)
15 slides from Creo Medical's investor presentation, March 2023
Slide 1: Bringing Advanced Energy to Endoscopy
Bringing Advanced Energy to Endoscopy Anything is Possible with the Right Approach
Slide 2: Disclaimer
Disclaimer IMPORTANT NOTICE This presentation comprises the written materials/slides (“presentation”) concerning Creo Medical Group PLC (the “Company”) and technologies and/or products developed or under development by the Company. By reviewing this presentation you agree to be bound by the followin
Slide 3: The Evolution of Advanced Energy
The Evolution of Advanced Energy Creo solves the challenge of energy in endoscopic and Creo focus complex robotic instruments 1990-2010 Advanced Robotic 1970-1990 Energy in Advanced Keyhole Flexible Energy Surgery Endoscopy Robotic surgery Surgical milestone accounts for only 5% of Open achieved whe
Slide 4: Creo Overview
2010 to 2015 Core technology R&D Creo Overview ▪ Angel, Venture and Strategic funding 2016 IPO on AIM 2017 First Regulatory Clearances • Creo solves the challenge of energy in endoscopic and complex robotic ▪ CE Mark and FDA for Croma and Speedboat instruments ▪ First patient treated with Speedboat
Slide 5: Creo Core Technology
Creo Core Technology Target Application: Speedboat is our flagship advanced • Bowel Resection energy device product with over 1,500 • Oesophagus procedures performed using the device • Stomach Surgical device combining Speedboat • Bowel . blade and precise microwave coagulation • Oesophagus in a uni
Slide 6: Market Sizing
Market Sizing Resection Ablation Robotics • c.$1bn TAM for lower GI Soft Tissue Procedures • Doctor interviews places Creo target market c.$100m US and EMEA within 5-7 years – Lower GI Speedboat only • Additional market potential for Speedboat c.$1.1bn c.$1bn for Upper GI procedures (est. 2031) • Si
Slide 7: Evolution of Speedboat User Base
Evolution of Speedboat User Base Pipeline User growth User forecast FY-22 FY-27 Year end users - Post Covid training, mentoring activity increasing rapidly - 4x user growth in FY22, expect 2-3x in FY23 - 2-3x cases completed growth in FY22, management forecast 3-4x in FY23 with introduction of new d
Slide 8: Conversion of Trainees to Users
Conversion of Trainees to Users - Increasing trainers, increasing trainees due to larger courses means more people that need mentoring - Courses run in all major regions of the US with smaller groups in '22, expected to get larger in '23 in partnership with ASGE and leading academic centers (UCI, Ma
Slide 9: MicroBlate Fine: Future Growth Product
MicroBlate Fine: Future Growth Product MicroBlate Fine Microwave Ablation (MWA) of NET Tumour 2022 Summary clinical usage EUS Guided MWA CT Scan 2 Months Post Ablation • 5 centres - Ecuador, France, Romania, India, Thailand • 25+ cases including Pancreatic and Liver cancer MicroBlate Homogeneous tis
Slide 10: MicroBlate Flex: Clinical Study for Lung
MicroBlate Flex: Clinical Study for Lung Ablate & Follow-up Study Ablate & Resect Study Confirm the clinical safety and feasibility in subjects with Confirm the clinical safety and feasibility in subjects with a single or multiple soft tissue lung lesions that is pathologically confirmed malignancy
Slide 11: Kamaptive IP Licensing Agreements
Kamaptive IP Licensing Agreements Creo technology is being adapted for use with robotic-assisted surgical platforms Intuitive: • ~70% surgical robotic market with an install base of over 7,800 systems • Multi-year collaboration agreement with Intuitive – a global technology leader in minimally invas
Slide 12: Kamaptive Potential – Robotics
Kamaptive Potential – Robotics Millions in year Two deals already signed (Intuitive and CMR Surgical) for initial devices • Ability to widen these relationships to additional devices • Ability to develop relationships with other Robotic Assisted Surgery 2031 companies Solid source of repeat and recu
Slide 13: Revenue Evolution
Revenue Evolution Significant Upside Management confident EBITDA breakeven in FY25 remains on track on Kamaptive not modelled EBITDA break even FY25 on track Base case, upsides include Creo Kamaptive • Bipolar devices Robotics based on • Additional Kamaptive Deals 2x announced deals - EMEA target pr
Slide 14: Feb/March 2023: Placing and Open Offer
Feb/March 2023: Placing and Open Offer • Raised £33.7m via an oversubscribed Placing and Open Offer • Resolves funding gap • Provides working capital required • Management expect funding to take Creo to cashflow breakeven and, ultimately, profitability • Speedboat usage patterns suggest accelerated
Slide 15: Slide 15
Creo Medical Group — Investor Presentation (March 2023) on 6ix